Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.40 |
| ▸ | POLA1 | P09884 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HINT1 | P49773 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534659 | 1.00 | KDM4E (0.49) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL2113123 | 0.90 | KDM4E (0.50) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL9790905 | 0.90 | ALDH1A1 (0.44) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL9801846 | 0.89 | TYMP (0.41) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL4553693 | 0.89 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL2113415 | 0.88 | TAS1R3 (0.40) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL441421 | 0.88 | TYMP (0.48) | KDM4ETAS1R3TAS1R1TYMPTAAR1 | |
| SCHEMBL8574965 | 0.86 | HPGD (0.46) | TYMPTAAR1HPGDPOLBHINT1 | |
| SCHEMBL11130624 | 0.86 | KDM4E (0.48) | KDM4ETAS1R3TAS1R1TYMPPOLA1 | |
| SCHEMBL6841553 | 0.86 | KDM4E (0.46) | KDM4ETAS1R3TAS1R1TYMPPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-12337291-B2 | Guide RNA synthesis system and method | SYNTHEGO CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20210047668-A1 | POLYMER SYNTHESIS SYSTEM AND METHOD | PERCEPTIVE CREDIT HOLDINGS III, LP | 2021-02-18 | — | — | US | disclosed |
| EP-3681637-A1 | BIOPOLYMER SYNTHESIS SYSTEM AND METHOD | Synthego Corporation (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20190076814-A1 | BIOPOLYMER SYNTHESIS SYSTEM AND METHOD | SYNTHEGO CORPORATION | 2019-03-14 | — | — | US | disclosed |
| WO-2019051430-A1 | BIOPOLYMER SYNTHESIS SYSTEM AND METHOD | SYNTHEGO CORPORATION (US) | 2019-03-14 | — | — | WO | disclosed |
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-7629447-B2 | Dideoxynucleoside derivatives | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| EP-0633890-A1 | SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | ZENECA LIMITED (GB) | 1995-01-18 | — | — | EP | disclosed |
| WO-1993020091-A1 | SUPPORT FOR OLIGONUCLEOTIDE SYNTHESIS | ZENECA LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
| WO-1993020092-A1 | SYNTHESIS OF OLIGONUCLEOTIDES | ZENECA LIMITED (GB) | 1993-10-14 | — | — | WO | disclosed |
| EP-0202758-B1 | HYBRIDIZATION METHOD AND PROBES THEREFOR | Zeneca Limited (GB) | 1991-09-25 | — | — | EP | disclosed |
| US-5043430-A | Process for treating insoluble heterologous protein | TOSOH CORPORATION (JP) | 1991-08-27 | — | — | US | disclosed |
| EP-0416817-A2 | Amplification processes | ZENECA LIMITED (GB) | 1991-03-13 | — | — | EP | disclosed |
| EP-0329175-A1 | Human nerve growth factor gene segment | Tosoh Corporation (JP) | 1989-08-23 | — | — | EP | disclosed |
| EP-0305201-A2 | Protected biotin derivatives | ZENECA LIMITED (GB) | 1989-03-01 | — | — | EP | disclosed |
| EP-0202758-A1 | Hybridization method and probes therefor | ZENECA LIMITED (GB) | 1986-11-26 | — | — | EP | disclosed |
| EP-0058954-A2 | Tridecadeoxynucleotide, process for its preparation and the application | Dr. Karl Thomae GmbH (DE) | 1982-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | KDM4E 4037/4885TAS1R3 3170/4885TAS1R1 2233/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | KDM4E 3231/4885TAS1R3 2846/4885TAS1R1 1960/4885 |
| US-20220127300-A1 | 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME | NT5C3B, DUT, RNGTT | KDM4E 3019/4885TAS1R3 3286/4885TAS1R1 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.